0
     

Report Added
Report already added
Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 6, 1, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 3 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diarrhea - Overview
Diarrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diarrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diarrhea - Companies Involved in Therapeutics Development
AbbVie Inc
Boston Pharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Cosmo Pharmaceuticals NV
DiscoveryBiomed Inc
Emergent BioSolutions Inc
First Wave BioPharma Inc
Glycosyn LLC
Hilleman Laboratories Pvt Ltd
Immuron Ltd
Jaguar Health Inc
Lumen Bioscience Inc
Microba Life Sciences Ltd
MyBiotics Pharma Ltd
Napo Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Nippon Shinyaku Co Ltd
Nuvara Therapeutics LLC
OnQuality Pharmaceuticals LLC
Orphomed Inc
Prokarium Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
Rebiotix Inc
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Synthetic Biologics Inc
Syntiron LLC
TenNor Therapeutics Ltd
Vanda Pharmaceuticals Inc
Vanessa Biotech
Wuhan Institute of Biological Products Co Ltd
Yisheng Biopharma Co Ltd
Zhiyi Pharmaceuticals Inc
Diarrhea - Drug Profiles
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antibody for Campylobacteriosis and Infectious Diarrhea - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZX-1101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
History of Events
BOS-589 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPO-27 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile
Product Description
Mechanism Of Action
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVD-1208S122 - Drug Profile
Product Description
Mechanism Of Action
diarrhea vaccine - Drug Profile
Product Description
Mechanism Of Action
diarrhea vaccine - Drug Profile
Product Description
Mechanism Of Action
Escherichia coli vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETEC vaccine - Drug Profile
Product Description
Mechanism Of Action
ETEC vaccine - Drug Profile
Product Description
Mechanism Of Action
Etvax - Drug Profile
Product Description
Mechanism Of Action
History of Events
FW-420 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
History of Events
IMSUTMR-1501 - Drug Profile
Product Description
Mechanism Of Action
History of Events
infectious diarrhea [serotype H11] vaccine - Drug Profile
Product Description
Mechanism Of Action
iOWH0-32 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lechlemer - Drug Profile
Product Description
Mechanism Of Action
History of Events
LMN-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MBXMC-101 - Drug Profile
Product Description
Mechanism Of Action
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
OQL-041 - Drug Profile
Product Description
Mechanism Of Action
OQL-061 - Drug Profile
Product Description
Mechanism Of Action
ORP-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Activate NHE-3 for Diarrhea - Drug Profile
Product Description
Mechanism Of Action
prulifloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ribaxamase - Drug Profile
Product Description
Mechanism Of Action
History of Events
rifamycin sodium CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
rotavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
shigella [serotype 2a] vaccine - Drug Profile
Product Description
Mechanism Of Action
Shylicine - Drug Profile
Product Description
Mechanism Of Action
SK-08 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYN-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYN-007 - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize DOR1 and MOR1 for Irritable Bowel Syndome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Typhetec - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Traveler's Diarrhea - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Traveler's Diarrhea - Drug Profile
Product Description
Mechanism Of Action
VS-002 - Drug Profile
Product Description
Mechanism Of Action
VS-014 - Drug Profile
Product Description
Mechanism Of Action
Diarrhea - Dormant Projects
Diarrhea - Discontinued Products
Diarrhea - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: Jaguar Health announces receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
Feb 01, 2022: Jaguar health announces completion of third-party, investigator-initiated study of crofelemer, which is expected to support orphan drug designation (ODD) for crofelemer for congenital diarrheal disorders (CDD)
Jan 13, 2022: Immuron receives European patent on drug composition to treat Travelers’ Diarrhea
Jan 12, 2022: Immuron awarded AU $6.2 million to clinically evaluate a military strength dosing regimen for Travelan
Jan 04, 2022: OrphoMed announces positive phase 2 results for ORP-101 100 mg once-daily dose in IBS-D patients
Nov 16, 2021: One hundredth patient enrolled in clinical trial of world's first 2-in-1 anti-diarrheal/oral rehydration solution
Nov 10, 2021: Immuron: US DoD Naval Medical Research Center clinical update
Oct 19, 2021: Vanessa Biotech receives approval from Ghana FDA to proceed with Cholera Phase II Clinical Trial
Aug 17, 2021: Jaguar Health subsidiary announces completion of additional preclinical study of Lechlemer (NP-300), the company's human drug product candidate for diarrhea relief from cholera and other acute infectious diarrhea
Jun 25, 2021: Vanessa Biotech registers VR-AD-1005, a novel antidiarrheal investigational drug, for phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera
Jun 01, 2021: Napo, Jaguar Health’s Italian subsidiary, provides updates on plans to pursue conditional marketing authorization in the EU
May 21, 2021: RedHill Biopharma presents a new travelers' diarrhea clinical severity classification tool and its use in Aemcolo efficacy analysis at DDW 2021
Apr 16, 2021: Jaguar Health announces upsizing of At-the-Market (ATM) Financing Program by $15.3 million with Ladenburg Thalmann & Co for potential future financing needs
Mar 22, 2021: FDA grants Orphan Drug Designation for Shylicine
Mar 01, 2021: The first children have been vaccinated in Scandinavian Biopharma’s large phase IIb study in The Gambia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Diarrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diarrhea - Pipeline by AbbVie Inc, 2022
Diarrhea - Pipeline by Boston Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, 2022
Diarrhea - Pipeline by DiscoveryBiomed Inc, 2022
Diarrhea - Pipeline by Emergent BioSolutions Inc, 2022
Diarrhea - Pipeline by First Wave BioPharma Inc, 2022
Diarrhea - Pipeline by Glycosyn LLC, 2022
Diarrhea - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
Diarrhea - Pipeline by Immuron Ltd, 2022
Diarrhea - Pipeline by Jaguar Health Inc, 2022
Diarrhea - Pipeline by Lumen Bioscience Inc, 2022
Diarrhea - Pipeline by Microba Life Sciences Ltd, 2022
Diarrhea - Pipeline by MyBiotics Pharma Ltd, 2022
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by NGM Biopharmaceuticals Inc, 2022
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, 2022
Diarrhea - Pipeline by Nuvara Therapeutics LLC, 2022
Diarrhea - Pipeline by OnQuality Pharmaceuticals LLC, 2022
Diarrhea - Pipeline by Orphomed Inc, 2022
Diarrhea - Pipeline by Prokarium Ltd, 2022
Diarrhea - Pipeline by Protagonist Therapeutics Inc, 2022
Diarrhea - Pipeline by RaQualia Pharma Inc, 2022
Diarrhea - Pipeline by Rebiotix Inc, 2022
Diarrhea - Pipeline by RedHill Biopharma Ltd, 2022
Diarrhea - Pipeline by RxBio Inc, 2022
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, 2022
Diarrhea - Pipeline by Synthetic Biologics Inc, 2022
Diarrhea - Pipeline by Syntiron LLC, 2022
Diarrhea - Pipeline by TenNor Therapeutics Ltd, 2022
Diarrhea - Pipeline by Vanda Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by Vanessa Biotech, 2022
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Diarrhea - Pipeline by Yisheng Biopharma Co Ltd, 2022
Diarrhea - Pipeline by Zhiyi Pharmaceuticals Inc, 2022
Diarrhea - Dormant Projects, 2022
Diarrhea - Dormant Projects, 2022 (Contd..1)
Diarrhea - Dormant Projects, 2022 (Contd..2)
Diarrhea - Discontinued Products, 2022

List of Figures
Number of Products under Development for Diarrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

India Blood Bags Market, By Product (Single Blood Bag, Triple Blood Bag, Double Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Type (Collection Bag v/s Transfer Bag), By Volume (450ml, 350ml, 150ml, 100ml, 250ml, Others), By Material (PVC, PET, Others), By End-User (Hospitals and Clinics, Blood Banks, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast & Opportunities, 2018-2028F

India Blood Bags Market, By Product (Single Blood Bag, Triple Blood Bag, Double Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Type (Collection Bag v/s Transfer Bag), By Volume (450ml, 350ml, 150ml, 100ml, 250ml, Others), By Material (PVC, PET, Others), By End-User (Hospitals and Clinics, Blood Banks, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast & Opportunities, 2018-2028F

Global Xenotransplantation Market By Animal Type (Pig, Rabbit, Baboon, Others), By Xeno Products (Organs, Tissues, Cells), By Organs (Kidney, Liver, Heart, Cornea, Others), By End Users (Transplants Center, Hospitals, Others), By Region, Competition Forecast & Opportunities, 2027

Global Xenotransplantation Market By Animal Type (Pig, Rabbit, Baboon, Others), By Xeno Products (Organs, Tissues, Cells), By Organs (Kidney, Liver, Heart, Cornea, Others), By End Users (Transplants Center, Hospitals, Others), By Region, Competition Forecast & Opportunities, 2027

Global Minimally Invasive Biopsy Techniques Market By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical v/s Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region, Competition Forecast & Opportunities, 2027

Global Minimally Invasive Biopsy Techniques Market By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical v/s Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region, Competition Forecast & Opportunities, 2027

Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027

Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027